Achieve Life Sciences Achieves 39% Quit Rate in Cytisinicline Retreatment Trial

For regulatory affairs leads tracking Achieve Life Sciences' path toward a potential NDA submission, 52-week open-label data from the ORCA-OL trial introduce a retreatment and extended-duration dataset that will require careful CMC and process validation alignment before any filing package is assembled.

The ORCA-OL trial enrolled 479 adults, of whom 475 received cytisinicline 3 mg three times daily for up to 52 weeks. The population was deliberately hard to treat: every participant had already completed a counseling-supported quit attempt in a prior ORCA trial, was still smoking or vaping, and elected to try again. Among those who smoked, the median number of prior quit attempts was five, and more than a third had previously tried varenicline, bupropion, or both. Mean participant age was 56 years; 86% were on concomitant medications, and many carried diagnoses of hypertension, depression, anxiety, cancer, or COPD.

Four-week sustained abstinence rates climbed across the treatment year: 25.5% at Weeks 9–12, 30.3% at Weeks 21–24, and 31.2% at Weeks 49–52 across the total study population. Among participants who had received placebo in their prior ORCA trial, the Week 49–52 quit rate reached 39.4%. Among those retreated after a prior cytisinicline course, 27.8% achieved abstinence at the same endpoint. The 73 exclusive e-cigarette users, the first vaping-specific cohort in a year-long cessation study, per the company, posted a 24.6% quit rate at Week 49–52, compared with 32.8% for exclusive smokers.

Median cytisinicline exposure was 361 days, with 69.7% of enrolled participants completing the full 52-week course. For plant heads and CMC teams, that completion rate and exposure duration carry direct implications: a commercial-scale manufacturing programme for a three-times-daily oral regimen sustained over a year demands robust process validation data, tightly controlled dissolution and content uniformity specifications, and a stability programme that covers the full intended shelf life under 21 CFR Part 211 and ICH Q10 quality system requirements.

The findings were presented at the CHEST 2026 Annual Meeting in Phoenix, Arizona on October 21, 2026. Achieve has not yet announced a formal NDA submission timeline, leaving CMC readiness and scale-up planning as the next measurable checkpoint for manufacturing and regulatory stakeholders to monitor.

Source: Achieve Life Sciences, Inc. via GlobeNewswire, October 21, 2026.